Magnetar Financial LLC Buys Shares of 27,860 TransMedics Group, Inc. (NASDAQ:TMDX)

Magnetar Financial LLC bought a new stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 27,860 shares of the company's stock, valued at approximately $1,737,000. Magnetar Financial LLC owned approximately 0.08% of TransMedics Group at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of the stock. Victory Capital Management Inc. increased its holdings in TransMedics Group by 11.3% during the 3rd quarter. Victory Capital Management Inc. now owns 4,569 shares of the company's stock worth $717,000 after purchasing an additional 464 shares during the period. Natixis Advisors LLC lifted its position in TransMedics Group by 29.8% during the third quarter. Natixis Advisors LLC now owns 78,073 shares of the company's stock valued at $12,258,000 after purchasing an additional 17,933 shares during the period. Mutual of America Capital Management LLC purchased a new stake in TransMedics Group in the 3rd quarter worth approximately $784,000. Thrivent Financial for Lutherans purchased a new stake in shares of TransMedics Group during the 3rd quarter worth about $4,113,000. Finally, Pathstone Holdings LLC grew its stake in TransMedics Group by 4.9% in the 3rd quarter. Pathstone Holdings LLC now owns 26,381 shares of the company's stock valued at $4,142,000 after acquiring an additional 1,231 shares during the period. 99.67% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several analysts recently issued reports on TMDX shares. JPMorgan Chase & Co. reaffirmed a "neutral" rating and set a $75.00 price objective (down previously from $116.00) on shares of TransMedics Group in a research note on Tuesday, December 17th. Canaccord Genuity Group restated a "buy" rating and set a $104.00 target price on shares of TransMedics Group in a report on Tuesday, March 11th. Piper Sandler dropped their price target on shares of TransMedics Group from $110.00 to $90.00 and set an "overweight" rating for the company in a research note on Wednesday, December 11th. Oppenheimer reaffirmed an "outperform" rating and issued a $125.00 target price on shares of TransMedics Group in a report on Tuesday, December 3rd. Finally, Robert W. Baird decreased their price target on TransMedics Group from $150.00 to $120.00 and set an "outperform" rating for the company in a report on Wednesday, December 11th. Three analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $122.70.

Remove Ads

TransMedics Group Stock Down 1.0 %

Shares of TMDX stock traded down $0.68 during trading hours on Tuesday, reaching $70.79. The company had a trading volume of 464,957 shares, compared to its average volume of 1,306,134. The stock's fifty day simple moving average is $68.27 and its 200 day simple moving average is $89.65. TransMedics Group, Inc. has a twelve month low of $55.00 and a twelve month high of $177.37. The company has a debt-to-equity ratio of 2.42, a quick ratio of 7.33 and a current ratio of 8.20. The company has a market capitalization of $2.38 billion, a P/E ratio of 75.31 and a beta of 2.12.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.